Neurocrine Biosciences’ New Drug May Cost Patients More Than $10,000 A Month, Twice As Much As Expected

Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about $64,000 a year.

That estimated 2018 price of $64,000 a year exceeds, if slightly, the range previously expected by Wall Street analysts at about $20,000 to $60,000 a year.

Back to news